<![CDATA[SAB Biotherapeutics, Inc. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=26613>Tue, 21 Apr 2026 18:40:44 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19]]>https://www.newswire.co.kr/newsRead.php?no=931142Tue, 28 Sep 2021 12:00:00 +0900<![CDATA[SAB 바이오세라퓨틱스, SAB-185에 대한 DSMB의 긍정적 평가 발표… 코로나19 치료 위한 NIH 후원 ACTIV-2 임상 3상 진행]]>https://www.newswire.co.kr/newsRead.php?no=931143Tue, 28 Sep 2021 12:00:00 +0900<![CDATA[SAB Biotherapeutics' Immunotherapy Proposal among Top Platform Technology Solutions in WHO Report]]>https://www.newswire.co.kr/newsRead.php?no=835772Thu, 22 Sep 2016 13:40:00 +0900<![CDATA[SAB의 면역치료 제안, WTO 보고서에서 최고의 플랫폼 기술 중 하나로 선정]]>https://www.newswire.co.kr/newsRead.php?no=835773Thu, 22 Sep 2016 13:40:00 +0900<![CDATA[SAB Biotherapeutics Produces New Human Antibody Treatment for MERS-CoV]]>https://www.newswire.co.kr/newsRead.php?no=817991Thu, 18 Feb 2016 13:55:00 +0900<![CDATA[SAB, 메르스 코로나바이러스에 대한 새 인간항체 치료제 생산]]>https://www.newswire.co.kr/newsRead.php?no=817992Thu, 18 Feb 2016 13:55:00 +0900